SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-010360
Filing Date
2021-02-18
Accepted
2021-02-18 17:05:07
Documents
7
Period of Report
2021-02-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea135980-8k_aikidopharma.htm 8-K 29618
2 AMENDED AND RESTATED UNDERWRITING AGREEMENT BY AND BETWEEN THE COMPANY AND H.C. ea135980ex1-1_aikidopharma.htm EX-1.1 210347
3 OPINION OF ELLENOFF GROSSMAN & SCHOLE LLP ea135980ex5-1_aikidopharma.htm EX-5.1 7284
4 FORM OF UNDERWRITER'S WARRANT ea135980ex10-1_aikidopharma.htm EX-10.1 103814
5 PRESS RELEASE DATED FEBRUARY 16, 2021 ea135980ex99-1_aikidopharma.htm EX-99.1 10750
6 GRAPHIC ex5-1_001.jpg GRAPHIC 3760
7 GRAPHIC ex99-1_001.jpg GRAPHIC 5296
  Complete submission text file 0001213900-21-010360.txt   376065
Mailing Address ONE ROCKEFELLER PLAZA, 11TH FLOOR NEW YORK NY 10020
Business Address ONE ROCKEFELLER PLAZA, 11TH FLOOR NEW YORK NY 10020 347-321-7646
AIkido Pharma Inc. (Filer) CIK: 0000012239 (see all company filings)

IRS No.: 520849320 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-05576 | Film No.: 21650461
SIC: 8731 Services-Commercial Physical & Biological Research